The suit alleges that thirty-six pharmaceutical companies and executives conspired to fix prices, allocate markets, and rig bids for dozens of generic drugs.
The dispute centers on whether Amneal participated in an overarching conspiracy to manipulate the generic drug market, as well as specific product-related conspiracies.
Judge Michael P. Shea denied the motion regarding Amneal's alleged participation in a conspiracy involving Phenytoin, an oral capsule used to treat epileptic seizures. This means the product-specific conspiracy claim against Amneal will proceed.
However, the judge granted summary judgment to Amneal on the overarching conspiracy claim, removing Amneal from that portion of the lawsuit.
The case involves complex manufacturing challenges for Phenytoin, which is classified as a narrow therapeutic index drug where small dosage differences can cause serious health risks.
Amneal faced supply issues with the drug, leading to "Failure-to-Supply" penalties and internal discussions about discontinuing the product due to low margins.
The ruling follows a previous decision by Judge Shea denying a joint motion for summary judgment on overarching conspiracy claims, finding sufficient evidence for a jury to consider the existence of such a conspiracy.
This case is one of three consolidated actions originally filed in Connecticut and transferred to the Eastern District of Pennsylvania before being remanded to Judge Shea in April 2024.